---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-051441"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:56:10.610261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Xilio reports Q4/FY 2024 results; cash $55.3M, AbbVie collaboration adds $52M upfront

## Summary
- Net loss of $13.1M in Q4 2024, $58.2M for FY 2024; license revenue $6.3M from Gilead deal.
- Cash $55.3M at Dec 31, 2024; plus $52M AbbVie upfront in Q1 2025 extends runway into Q1 2026.
- Vilastobart Phase 2 in MSS CRC: 27% ORR in patients without liver metastases; colitis 5%.
- Collaboration with AbbVie: up to $2.1B total payments plus royalties; develop masked T cell engagers.
- Plan to nominate development candidates for PSMA (Q3 2025), CLDN18.2 (Q4 2025), STEAP1 (H1 2026).

## SEC filing metadata
- accession: 0001193125-25-051441
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312525051441/0001193125-25-051441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312525051441/d890896d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-051441
- JSON: https://secwatch.observer/filing/0001193125-25-051441.json
- Plain text: https://secwatch.observer/filing/0001193125-25-051441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.